RecruitingPhase 2NCT06749691
Liposomal Irinotecan and Apatinib in ES-SCLC
Study of Liposomal Irinotecan Combined with Apatinib in the Treatment of Extensive Stage Small Cell Lung Cancer After First-line Progression
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment
30 participants
Start Date
Dec 28, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria4
- Age range of 18-75 years;
- Expected survival period ≥ 12 weeks;
- At least one measurable lesion (according to RECIST V 1.1);
- For patients who have failed first-line or second-line treatment.
Exclusion Criteria4
- Have received any systemic treatment targeting VEGF or VEGFR in the past, such as treatment with anti angiogenic drugs such as ranibizumab, fipronib, apatinib, anlotinib, lenvatinib, sunitinib, sorafenib.
- Active or uncontrolled severe infection (CTCAE 5.0 ≥ 2) and/or antibiotic treatment within 2 weeks prior to enrollment;
- There are multiple factors that affect the absorption of oral medication, such as inability to swallow, nausea and vomiting, chronic diarrhea, and intestinal obstruction;
- Those deemed unsuitable for inclusion by doctors;
Interventions
DRUGLiposomal Irinotecan and Apatinib
Liposomal Irinotecan in Combination With Apatinib
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06749691
Related Trials
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT072275972 locations
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
NCT066107341 location
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
NCT071399901 location
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT0570397117 locations
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT069542461 location